Australia's most trusted
source of pharma news
Posted 29 July 2025 AM
A survey of neurologists used open-ended questions to capture unaided, top-of-mind recall for both approved and pipeline neurology drugs - and found that no single drug had greater than five per cent mindshare.
The neurology therapeutic landscape is one of the most intensely competitive, with hundreds of drugs vying for the attention of prescribers. This creates a significant challenge for pharmaceutical marketers trying to break through the noise to attract a neurologist's attention.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.